Peptide ChooserBPC-157 vs TB-500: FDA status, evidence and prices side by side.
Short answer
Neither BPC-157 nor TB-500 is FDA approved for any use.1 For each, its nomination for pharmacy compounding was withdrawn.2 In July 2026 the FDA proposed not to let pharmacies use either one.3 For BPC-157 we found three small studies in people, rated very low in certainty; for TB-500 the FDA found no human data.42
What are BPC-157 and TB-500?
BPC-157 is a lab-made peptide of 15 amino acids, popular for recovery from muscle and tendon injuries.4 TB-500 is a short piece of a larger body protein, thymosin beta-4: the fragment found in TB-500 products is seven amino acids long.72
Both are sold by research-use shops as powder in a vial, often side by side and sometimes in one blend.
What is the FDA status of each?
- BPC-157: not approved: its nomination for pharmacy compounding was withdrawn.2
- TB-500: not approved: its nomination for pharmacy compounding was withdrawn.2
On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee reviewed both, and the FDA proposed not to allow pharmacies to use them to make medicines.3 The FDA says both may set off an immune reaction when given some ways.2 Our guide Is BPC-157 legal? explains the review.
What do the studies show?
For BPC-157, most of the research is in animals. A 2026 review found three studies in people, with 30 people in all: two looked back at patients treated for knee pain or a bladder condition, and one tested its safety in two people. The reviewers rated the evidence very low in certainty.4
For TB-500, the FDA says it found no data on its use in people.2 We found no trial in people either.
How do the FDA's concerns compare?
The FDA lists both among the substances that may be risky when pharmacies use them to make medicines, for slightly different reasons.2
- BPC-157: it may set off an immune reaction when given some ways, it may be hard to make without unwanted peptide fragments, and the FDA found no, or only limited, safety information for the ways it was proposed to be used.2
- TB-500: it may set off an immune reaction because the peptide can clump together or carry unwanted fragments, and the FDA found no data on its use in people, so it does not know whether it would cause harm.2
In both cases the FDA's point is the same: there is too little information to know what the product does to a person.
What do people buy them for?
Our recovery page describes each one:
- BPC-157: The most searched "healing peptide". Animal studies only; the FDA reviewed it for pharmacy compounding on 23 Jul 2026 and proposed keeping it off the list.
- TB-500: A copy of a natural repair protein, sold alongside BPC-157. Same July 2026 review, same proposal.
Those are the claims shops make. Neither has been shown in a trial in people to speed recovery.
What do they cost?
- 78 shops we track list BPC-157; the middle price across their listings is $5.95 per mg.5 The lowest price per mg in our BPC-157 window is $1.14 (Chimera Peptides).5
- 75 shops we track list TB-500; the middle price across their listings is $6.65 per mg.5 The lowest price per mg in our TB-500 window is $1.28 (Go Alpha Labs).5
The window on our recovery page lists each shop with its five checks; we never link to the shops. You can also put two shops side by side on Compare.
What has the FDA said to the shops?
Of the 172 FDA warning letters on our letters page, 20 went to research-use peptide shops, the kind that sell both.6
A warning letter is the FDA's formal notice, not a court ruling.8 Our guide on what an FDA warning letter means explains what follows one.
So which is better?
Neither has the evidence in people to answer that. Both are not approved, both were reviewed by the FDA in July 2026, and both have little or no human data. A lower price per mg does not make one a better choice.
None of this is medical advice. A doctor or physical therapist can tell you what helps your injury.
What to do next
Sources
- Drugs@FDA, searched through openFDA for BPC-157, GHK-Cu (also as copper tripeptide and prezatide) and TB-500 (also as thymosin beta-4): no approved product, 2 Nov 2026: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
- FDA, Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks, current as of 22 Apr 2026: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting, 23 and 24 Jul 2026 (BPC-157, TB-500, MOTS-c, epitalon): https://www.fda.gov/media/193342/download
- Poolton JT et al., Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review, Acta Orthop Belg 92(3), 2026, PubMed 42885452: https://pubmed.ncbi.nlm.nih.gov/42885452/
- Peptide Chooser database: the research-use and cosmetic peptide shops we check, 2 Nov 2026. Their prices and checks are in the seller windows on our goal pages
- Peptide Chooser, FDA warning letters to peptide sellers, compounders and online clinics, checked 2 Nov 2026
- Esposito S et al., The N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, Drug Test Anal 4(9), 2012, PubMed 22962027: https://pubmed.ncbi.nlm.nih.gov/22962027/
- FDA, About Warning and Close-Out Letters, current as of 20 Mar 2024: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/about-warning-and-close-out-letters